spironolactone has been researched along with Impaired Glucose Tolerance in 9 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone." | 9.51 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. ( Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Hazebroek, MR; Henkens, MHTM; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pizard, A; Rossignol, P; Verdonschot, JAJ; Waring, OJ; Zannad, F, 2022) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| " Here, we investigated the effect of SPL on blood glucose levels in SHR/NDmcr-cp(cp/cp) (ND) rats, an animal model of metabolic syndrome, in comparison with that of eplerenone (EPL), another MR antagonist." | 7.78 | Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. ( Arai, K; Fujisawa, M; Homma, T; Ikeda, M; Ishii, M; Sada, T, 2012) |
| " We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone." | 5.51 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. ( Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Hazebroek, MR; Henkens, MHTM; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pizard, A; Rossignol, P; Verdonschot, JAJ; Waring, OJ; Zannad, F, 2022) |
| " The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes." | 5.27 | A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. ( Bernier, M; Chaar, D; de Denus, S; Ducharme, A; Guertin, MC; Jutras, M; Korol, S; Lavoie, J; Leclair, G; Liszkowski, M; Mansour, A; Neagoe, PE; O'Meara, E; Racine, N; Rouleau, JL; Sirois, MG; Tournoux, F; White, M, 2018) |
| "The October 2010 ESHRE/ASRM polycystic ovary syndrome (PCOS) workshop concluded: (1) all combined oral contraceptives (COC) appear to have equal efficacy for PCOS, (2) addition of antiandrogens (spironolactone) to COCs has little treatment benefit and (3) metformin does not improve the live-birth rate and should only be used with impaired glucose tolerance." | 3.79 | Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. ( Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| " Here, we investigated the effect of SPL on blood glucose levels in SHR/NDmcr-cp(cp/cp) (ND) rats, an animal model of metabolic syndrome, in comparison with that of eplerenone (EPL), another MR antagonist." | 3.78 | Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. ( Arai, K; Fujisawa, M; Homma, T; Ikeda, M; Ishii, M; Sada, T, 2012) |
| "Primary hyperaldosteronism (PH) is frequently considered to be a secondary form of diabetes mellitus (DM)." | 1.32 | Does the treatment of primary hyperaldosteronism influence glucose tolerance? ( Sindelka, G; Skrha, J; Strauch, B; Widimský, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Verdonschot, JAJ | 1 |
| Ferreira, JP | 1 |
| Pizard, A | 1 |
| Pellicori, P | 1 |
| Brunner La Rocca, HP | 1 |
| Clark, AL | 1 |
| Cosmi, F | 1 |
| Cuthbert, J | 1 |
| Girerd, N | 1 |
| Waring, OJ | 1 |
| Henkens, MHTM | 1 |
| Mariottoni, B | 1 |
| Petutschnigg, J | 1 |
| Rossignol, P | 1 |
| Hazebroek, MR | 1 |
| Cleland, JGF | 1 |
| Zannad, F | 1 |
| Heymans, SRB | 1 |
| Korol, S | 1 |
| White, M | 1 |
| O'Meara, E | 1 |
| Tournoux, F | 1 |
| Racine, N | 1 |
| Ducharme, A | 1 |
| Rouleau, JL | 1 |
| Liszkowski, M | 1 |
| Mansour, A | 1 |
| Jutras, M | 1 |
| Guertin, MC | 1 |
| Bernier, M | 1 |
| Lavoie, J | 1 |
| Leclair, G | 1 |
| Neagoe, PE | 1 |
| Chaar, D | 1 |
| Sirois, MG | 1 |
| de Denus, S | 1 |
| Muneyyirci-Delale, O | 1 |
| Co, S | 1 |
| Winer, N | 1 |
| Sherajee, SJ | 1 |
| Rafiq, K | 1 |
| Nakano, D | 1 |
| Mori, H | 1 |
| Kobara, H | 1 |
| Hitomi, H | 1 |
| Fujisawa, Y | 1 |
| Kobori, H | 1 |
| Masaki, T | 1 |
| Nishiyama, A | 1 |
| Armani, A | 1 |
| Cinti, F | 1 |
| Marzolla, V | 1 |
| Morgan, J | 1 |
| Cranston, GA | 1 |
| Antelmi, A | 1 |
| Carpinelli, G | 1 |
| Canese, R | 1 |
| Pagotto, U | 1 |
| Quarta, C | 1 |
| Malorni, W | 1 |
| Matarrese, P | 1 |
| Marconi, M | 1 |
| Fabbri, A | 1 |
| Rosano, G | 1 |
| Cinti, S | 1 |
| Young, MJ | 1 |
| Caprio, M | 1 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ganie, MA | 1 |
| Ammini, AC | 1 |
| Homma, T | 1 |
| Fujisawa, M | 1 |
| Arai, K | 1 |
| Ishii, M | 1 |
| Sada, T | 1 |
| Ikeda, M | 1 |
| Bird, ST | 1 |
| Hartzema, AG | 1 |
| Etminan, M | 1 |
| Brophy, JM | 1 |
| Delaney, JA | 1 |
| Strauch, B | 1 |
| Widimský, J | 1 |
| Sindelka, G | 1 |
| Skrha, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450] | Phase 2 | 528 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes.[NCT01586442] | Phase 3 | 62 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for spironolactone and Impaired Glucose Tolerance
| Article | Year |
|---|---|
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Topics: Biomarkers; Female; Glucose Intolerance; Heart Failure; Humans; Male; Mineralocorticoid Receptor Ant | 2022 |
A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Female; | 2018 |
7 other studies available for spironolactone and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.
Topics: Adult; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Elasticity; Female; Glucose Intoler | 2018 |
Aldosterone aggravates glucose intolerance induced by high fructose.
Topics: Aldosterone; Animals; Blood Glucose; Fructose; Glucose Intolerance; Glucose Tolerance Test; Immediat | 2013 |
Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Androstenes; An | 2014 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome.
Topics: Animals; Area Under Curve; Blood Glucose; Eplerenone; Glucose; Glucose Intolerance; Metabolic Syndro | 2012 |
Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines.
Topics: Androgen Antagonists; Contraceptives, Oral, Combined; Databases, Factual; Drug Prescriptions; Female | 2013 |
Does the treatment of primary hyperaldosteronism influence glucose tolerance?
Topics: Adrenalectomy; Adult; Blood Glucose; Blood Pressure; Combined Modality Therapy; Female; Glucose Into | 2003 |